Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.46 |
| ▸ | ITGAV | P06756 | 6/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.46 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 9/20 | 0.43 |
| ▸ | MC5R | P33032 | 9/20 | 0.43 |
| ▸ | MC3R | P41968 | 9/20 | 0.43 |
| ▸ | MC1R | Q01726 | 9/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19102258 | 1.00 | ITGB3 (0.46) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL19605457 | 0.88 | ITGB3 (0.57) | ITGB3ITGAVITGB5ITGA2BITGB1 | |
| SCHEMBL24253307 | 0.88 | ITGB3 (0.57) | ITGB3ITGAVITGB5ITGA2BITGB1 | |
| SCHEMBL19939614 | 0.87 | ITGB3 (0.44) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL21348134 | 0.87 | ITGB3 (0.44) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL19940184 | 0.81 | ITGB3 (0.41) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL16477811 | 0.81 | MC4R (0.44) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL15397366 | 0.81 | ITGB3 (0.60) | ITGB3ITGAVITGB5ITGA2BITGB1 | |
| SCHEMBL10138534 | 0.81 | ITGB3 (0.60) | ITGB3ITGAVITGB5ITGA2BITGB1 | |
| SCHEMBL278647 | 0.81 | CACNA1B (0.46) | ITGB3ITGAVITGB5ITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701694-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | THE UNIVERSITY OF MELBOURNE (AU) | 2017-07-11 | — | — | US | disclosed |
| US-20110293517-A1 | Nitrogen-Containing Macrocyclic Conjugates As Radiopharmaceuticals | THE UNIVERSITY OF MELBOURNE (AU) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110293517-A1 | Nitrogen-Containing Macrocyclic Conjugates As Radiopharmaceuticals | NCL, NUDC, C3AR1 | ITGB3 516/4885ITGAV 814/4885ITGB5 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.